Matthew Sykes
Stock Analyst at Goldman Sachs
(3.86)
# 633
Out of 4,876 analysts
205
Total ratings
52.11%
Success rate
7.92%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $5.20 | -3.85% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $3.55 | -15.49% | 9 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $11.70 | -44.44% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $42.18 | +6.69% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $5.33 | +50.09% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $36.94 | +29.94% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $11.36 | +49.65% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $146.75 | +9.03% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $7.16 | +39.66% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $98.79 | +26.53% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $13.74 | +1.89% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $201.46 | +19.13% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $19.29 | +34.78% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $151.59 | +12.14% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $50.03 | +11.93% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $89.59 | -10.70% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.29 | +16.28% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $168.17 | +12.98% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $0.81 | +116.85% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $2.38 | +78.57% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $26.81 | +38.01% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $51.81 | +25.46% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $158.16 | +58.07% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $6.57 | +265.30% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,193.31 | +8.94% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $9.61 | +24.87% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $412.12 | +55.29% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $119.42 | +21.42% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $48.04 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $5.20
Upside: -3.85%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $3.55
Upside: -15.49%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $11.70
Upside: -44.44%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $42.18
Upside: +6.69%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $5.33
Upside: +50.09%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $36.94
Upside: +29.94%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $11.36
Upside: +49.65%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $146.75
Upside: +9.03%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $7.16
Upside: +39.66%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $98.79
Upside: +26.53%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $13.74
Upside: +1.89%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $201.46
Upside: +19.13%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $19.29
Upside: +34.78%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $151.59
Upside: +12.14%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $50.03
Upside: +11.93%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $89.59
Upside: -10.70%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.29
Upside: +16.28%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $168.17
Upside: +12.98%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $0.81
Upside: +116.85%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $2.38
Upside: +78.57%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $26.81
Upside: +38.01%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $51.81
Upside: +25.46%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $158.16
Upside: +58.07%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $6.57
Upside: +265.30%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,193.31
Upside: +8.94%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $9.61
Upside: +24.87%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $412.12
Upside: +55.29%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $119.42
Upside: +21.42%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $48.04
Upside: -